Source Nature Detailed analysis of misconduct investigations into huge research fraud suggests institutional probes aren’t rigorous enough. By day, Andrew Grey studies bone health. But over the past few years, he’s developed another speciality: the case of one of science’s most prolific fraudsters. From 1996 to 2013, Yoshihiro Sato, a Japanese bone-health researcher plagiarized work,
Research supported by the Accelerating Medicines Partnership (AMP) on Rheumatoid Arthritis and Systemic Lupus Erythematosus (RA/SLE) provides new insights into tissue damage for these autoimmune conditions. Findings include the identification of novel molecular signatures related to immune system signaling in kidney cells that may reflect their active role in disease process; molecular targets, including specific white blood
Nutrigenomics — the nexus of nutrition, genetics and genomics — is still in its infancy, but USC researcher Cary Kreutzer sees vast potential in its ability to help people take control of their health. ne day, you may walk into your doctor’s office and come out with a diet that’s been personalized for your unique
The U.S. Food and Drug Administration today approved Emgality (galcanezumab-gnlm) solution for injection for the treatment of episodic cluster headache in adults. “Emgality provides patients with the first FDA-approved drug that reduces the frequency of attacks of episodic cluster headache, an extremely painful and often debilitating condition,” said Eric Bastings, M.D., deputy director of the
Michigan State University physicians have found that vitamin D, if taken for at least three years, could help cancer patients live longer. The findings suggest that the vitamin carries significant benefits other than just contributing to healthy bones and were presented at the American Society of Clinical Oncology annual meeting on June 3, 2019. In
The US Food and Drug Administration (FDA) has approved Piqray (alpelisib) tablets to treat patients with breast cancer. Piqray is to be used in combination with the FDA-approved endocrine therapy, fulvestrant, to treat post-menopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer (as detected by
In research published this week, scientists have found that a therapy originally developed to treat Alzheimer’s Disease could hold promise for children with T-cell acute lymphoblastic leukaemia. An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and Children’s Cancer Institute, Australia, have identified a novel therapy for T-cell acute lymphoblastic leukaemia
Source The Guardian International Life Sciences Institute used by corporate backers to counter public health policies, says study An institute whose experts have occupied key positions on EU and UN regulatory panels is, in reality, an industry lobby group that masquerades as a scientific health charity, according to a peer-reviewed study. The Washington-based International Life Sciences
The international, randomised phase III MONALEESA-7 trial found that adding ribociclib to standard-of-care endocrine therapy significantly improved overall survival for premenopausal women with advanced HR-positive/HER2-negative breast cancer compared with endocrine therapy alone. After 42 months of follow-up, the survival rate was 70% for women who took the combination therapy compared with 46% for women who
Study finds engaging young children in conversation is more important for brain development than “dumping words” on them. A landmark 1995 study found that children from higher-income families hear about 30 million more words during their first three years of life than children from lower-income families. This “30-million-word gap” correlates with significant differences in tests
